Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries to drive functions of the microbiome organ, today announced that it has closed $101 million in an oversubscribed Series C financing. Several new […]
After 10 years and a worldwide effort, Crohn’s and Colitis Canada is pleased to announce that the world-renowned Genetic, Environmental, Microbial (GEM) Project has reached its goal of 5,000 participants. Launched in 2008 at Mount […]
Previously, Isabelle Ducellier has held a number of senior international positions within the Pernod Ricard Group for 20 years, mainly within sales and marketing. She completed her career there as CEO and Board member of […]
MaaT Pharma, a clinical-stage microbiome therapy company, and SATT Lutech, a private technology transfer company holding the exclusive rights to the scientific findings from research groups at Sorbonne University, APHP, CNRS and INSERM, today announced […]
Building upon the recently announced partnership with TFTAK in March 2018, the DuPont Nutrition & Health Microbiome Venture continues to strengthen its capabilities in announcing the third strategic research and development partnership. The newly forged […]
CosmosID, a bioinformatics provider and NGS service laboratory, announced that the company’s cloud-based bioinformatics platform for microbiome analysis has received the highest score in the strain-level microbial profiling category of the Mosaic Community Challenge and […]
The use of probiotics has skyrocketed in recent years, with more than 3.9 million American adults taking probiotics.1 At the same time, there is limited scientific data supporting the health claims of probiotics, as well […]
Kallyope Inc. and Novo Nordisk A/S today announced that they have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes. Kallyope will receive an upfront payment […]
Parkinson’s Institute and Clinical Center (PICC) and Axial Biotherapeutics announced a collaboration to investigate interventions targeting gastrointestinal (GI) metabolites that may cause Parkinson’s Disease (PD). The interventions, to be developed and identified by Axial, will […]
Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC). […]
This year Probiota Americas took microbiome stakeholders to Miami to learn about new prebiotics and probiotics, about the shift of the market to internet, what next-generation analytical tools will drive the future, and much more. […]